Dapagliflozin and cardiovascular events in type 2 diabetes : the model of the DECLARE-TIMI 58 trialPrécédent
Résumé de l'article :
This paper aimed to review the clinical data on dapagliflozin (Forxiga®) treatment in the light of the recent DECLARE-TIMI 58 trial results. This study involving Type 2 diabetic patients, either with or without prior macroangiopathy, has demonstrated cardiovascular benefits in terms of the primary efficacy outcome, namely a composite of cardiovascular death and hospitalization for heart failure. Moreover, the study has revealed a lower risk for renal disease progression.
What does this article bring up for us?
The EMPA-REG OUTCOME and CANVAS trials have both evidenced cardiovascular benefits in Type 2 diabetic patients, with established CV disease in the majority of them. The DECLARE-TIMI 58 was a trial including a broader patient population with about 60% of them in primary cardiovascular prevention. Therefore, this study adds significant clinical information, in addition to the two previous randomized trials with SGLT-2 inhibitors, essentially demonstrating a lower risk for heart failure-induced hospitalizations in patients undergoing dapagliflozin vs. placebo therapy.
Dapagliflozin, DECLARE-TIMI 58, primary and secondary cardiovascular prevention, cardiovascular events, heart failure, nephropathy
Pour lire l'article en entier, merci de vous connecter
Déja membre ?
Pas encore membre ?
Cliquez ici pour débuter la procédure